Comparative Pharmacology
Head-to-head clinical analysis: FUZEON versus PENCICLOVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUZEON versus PENCICLOVIR.
FUZEON vs PENCICLOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fusion inhibitor; binds to gp41 of HIV-1, preventing conformational changes required for fusion with host CD4+ T-cell membrane.
Penciclovir is a nucleoside analog that inhibits viral DNA polymerase. It is phosphorylated by viral thymidine kinase to penciclovir triphosphate, which competitively inhibits viral DNA polymerase and terminates DNA chain elongation.
90 mg subcutaneously twice daily
Topical: Apply 1% cream every 2 hours while awake (approximately 9 times/day) for 4 days. Oral: 500 mg twice daily for 5 days.
None Documented
None Documented
Terminal elimination half-life: 3.8 hours; clinically, steady-state plasma concentrations are achieved within 2-3 days with subcutaneous administration
Terminal half-life: 2.0–2.5 hours (healthy adults); prolonged to ~9–10 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjusted based on renal function.
Renal: approximately 70% as unchanged drug via glomerular filtration; fecal: <5% as metabolites
Renal excretion: >70% as unchanged penciclovir via glomerular filtration and tubular secretion.
Category C
Category A/B
Antiviral
Antiviral